Approximately 80% of pediatric T-ALL patients exhibit elevated levels of β-catenin compared to healthy controls, resulting in abnormal activation of β-catenin-dependent genes such as survivin, c-Myc, TCF1, and LEF [98]. This evidence concerns the gene MYC and acute lymphoblastic leukemia.